Prognostic and predictive value of c-erbB-2 (HER-2/neu) gene amplification in human Breast Cancer

Breast Cancer ◽  
2001 ◽  
Vol 8 (1) ◽  
pp. 38-44 ◽  
Author(s):  
Hitoshi Tsuda
Keyword(s):  
Breast Cancer ◽  
Gene Amplification ◽  
Predictive Value ◽  
Human Breast Cancer ◽  
Human Breast ◽  
Her 2

Assessment of Methods for Tissue-Based Detection of the HER-2/neu Alteration in Human Breast Cancer: A Direct Comparison of Fluorescence In Situ Hybridization and Immunohistochemistry

2000 ◽  
Vol 18 (21) ◽  
pp. 3651-3664 ◽  
Author(s):  
Giovanni Pauletti ◽  
Suganda Dandekar ◽  
HongMei Rong ◽  
Lilllian Ramos ◽  
HongJun Peng ◽  
...  
Keyword(s):  
Breast Cancer ◽  
In Situ Hybridization ◽  
Fluorescence In Situ Hybridization ◽  
Gene Amplification ◽  
Survival Probability ◽  
Human Breast Cancer ◽  
Patient Survival ◽  
Human Breast ◽  
Her 2

PURPOSE: To compare the efficacy of fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC) in detecting the HER-2/neu alteration in human breast cancer. PATIENTS AND METHODS: Unselected stage I, II, and III breast cancer patients (N = 900) were tested for HER-2/neu gene amplification by FISH in paraffin-embedded, formalin-fixed archival material. Of these samples, 856 were tested for HER-2/neu overexpression by non–antigen-retrieval IHC with the polyclonal antibody R60, the sensitivity and specificity of which was preliminarily compared with the United States Food and Drug Administration–approved HercepTest (Dako Corp, Carpinteria, CA). Patient survival was analyzed in relation to the presence of the HER-2/neu alteration as determined by these two methodologies. RESULTS: A total of 189 (21%) of 900 patients were positive by FISH and 147 (17.2%) of 856 were positive by IHC. This discrepancy is consistent with expected loss of IHC sensitivity associated with tissue fixation/embedding. The HercepTest did not improve sensitivity and introduced false positives. Comparison of R60-based IHC with FISH demonstrates that patient survival is associated progressively to gene amplification level as determined by FISH, whereas for IHC an association is found only in the highest (3+) immunostaining group. Among FISH-negative tumors, 45 (6.6%) of 678 were IHC-positive, with a survival probability similar to that of FISH-negative/IHC-negative cases; FISH-positive/IHC-negative patients have a survival probability similar to that of FISH-positive/IHC-positive cases. CONCLUSION: IHC does not consistently discriminate patients likely to have a poor prognosis, whereas FISH provides superior prognostic information in segregating high-risk from lower-risk beast cancers. HER-2/neu protein overexpression in the absence of gene amplification occurs infrequently in breast cancer, in which case, patient outcome is similar to that of patients without the alteration.

scholarly journals HER-2 gene amplification in human breast cancer without concurrent HER-2 over-expression

SpringerPlus ◽  
2013 ◽  
Vol 2 (1) ◽  
Author(s):  
Shiuh-Wen Luoh ◽  
Betsy Ramsey ◽  
Amy Hanlon Newell ◽  
Megan Troxell ◽  
Zhi Hu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Gene Amplification ◽  
Human Breast Cancer ◽  
Human Breast ◽  
Over Expression ◽  
Her 2

Jab1 is overexpressed in human breast cancer and is a downstream target for HER-2/neu

2008 ◽  
Author(s):  
Ming-Chuan Hsu ◽  
Chee-Yin Chai ◽  
Ming-Feng Hou ◽  
Hui-Chiu Chang ◽  
Wan-Tzu Chen ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Human Breast Cancer ◽  
Human Breast ◽  
Downstream Target ◽  
Her 2

Decreased Response to Paclitaxel Versus Docetaxel in HER-2/neu Transfected Human Breast Cancer Cells

2003 ◽  
Vol 26 (1) ◽  
pp. 50-54 ◽  
Author(s):  
Lois M. Witters ◽  
Samuel M. Santala ◽  
Linda Engle ◽  
Vernon Chinchilli ◽  
Allan Lipton
Keyword(s):  
Breast Cancer ◽  
Cancer Cells ◽  
Human Breast Cancer ◽  
Breast Cancer Cells ◽  
Human Breast Cancer Cells ◽  
Human Breast ◽  
Her 2
Sign in / Sign up

Export Citation Format

Share Document